MD3119C2 - Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei - Google Patents

Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei

Info

Publication number
MD3119C2
MD3119C2 MDA20020212A MD20020212A MD3119C2 MD 3119 C2 MD3119 C2 MD 3119C2 MD A20020212 A MDA20020212 A MD A20020212A MD 20020212 A MD20020212 A MD 20020212A MD 3119 C2 MD3119 C2 MD 3119C2
Authority
MD
Moldova
Prior art keywords
molsidomine
hours
released
drug form
oral use
Prior art date
Application number
MDA20020212A
Other languages
English (en)
Russian (ru)
Other versions
MD3119B2 (ro
MD20020212A (ro
Inventor
Джозеф-Мишель ГЕЗИ
Original Assignee
Therabel Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Limited filed Critical Therabel Pharmaceuticals Limited
Publication of MD20020212A publication Critical patent/MD20020212A/ro
Publication of MD3119B2 publication Critical patent/MD3119B2/ro
Publication of MD3119C2 publication Critical patent/MD3119C2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Invenţia se referă la o formă medicamentoasă pentru administrare orală cu eliberare prelungită a molsidominei şi poate fi utilizată în tratamentul tuturor formelor de stenocardie (stenocardie de efort sau de repaus, stare de preinfarct).Esenţa invenţiei constă în aceea că forma medicamentoasă conţine o cantitate terapeutic eficientă de molsidomină sau unul din metaboliţii săi activi, selectat dintre SIN-1 şi SIN-1A, având un indice de dizolvare in vitro [măsurat spectrofotometric la 286 sau 311 nm după metoda descrisă în European Pharmacopeia, ediţia a 3-a (sau USP XXIV), la 50 rot./min, în 500 ml de 0,1 N HCl, la 37°C] de: 15...25% de molsidomină eliberată după 1 oră, 20...35% eliberată după 2 ore, 50...65% eliberată după 6 ore, 75...95% eliberată după 12 ore, mai mult de 85% eliberată după 18 ore şi mai mult de 90% de molsidomină eliberată după 24 ore, concentraţia maximă de molsidomină în plasmă in vivo, şi anumede 25…40 ng/ml se obţine de la 2,5 la 5 ore, preferabil de la 3 la 4 ore după administrarea formei menţionate.
MDA20020212A 2000-02-24 2001-02-22 Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei MD3119C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002307A FR2805462B1 (fr) 2000-02-24 2000-02-24 Nouvelle forme galenique orale a liberation prolongee de la molsidomine
PCT/EP2001/002055 WO2001062256A1 (fr) 2000-02-24 2001-02-22 Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Publications (3)

Publication Number Publication Date
MD20020212A MD20020212A (ro) 2002-12-31
MD3119B2 MD3119B2 (ro) 2006-08-31
MD3119C2 true MD3119C2 (ro) 2007-04-30

Family

ID=8847342

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20020212A MD3119C2 (ro) 2000-02-24 2001-02-22 Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei

Country Status (36)

Country Link
US (1) US7767227B2 (ro)
EP (1) EP1265614B1 (ro)
JP (1) JP4945043B2 (ro)
KR (1) KR100814191B1 (ro)
CN (1) CN100396284C (ro)
AT (1) ATE296632T1 (ro)
AU (2) AU4065301A (ro)
BE (1) BE1013487A3 (ro)
BG (1) BG66111B1 (ro)
BR (1) BRPI0108041B8 (ro)
CA (1) CA2400886C (ro)
CZ (1) CZ301993B6 (ro)
DE (1) DE60111196T2 (ro)
DZ (1) DZ3273A1 (ro)
EE (1) EE05098B1 (ro)
ES (1) ES2241803T3 (ro)
FR (1) FR2805462B1 (ro)
HK (1) HK1050138B (ro)
HR (1) HRP20020692B1 (ro)
HU (1) HU229799B1 (ro)
IL (2) IL151205A0 (ro)
IS (1) IS2446B (ro)
MA (1) MA25576A1 (ro)
MD (1) MD3119C2 (ro)
MX (1) MXPA02008262A (ro)
NO (1) NO329495B1 (ro)
NZ (1) NZ520691A (ro)
OA (1) OA12183A (ro)
PL (1) PL201631B1 (ro)
PT (1) PT1265614E (ro)
RS (1) RS50291B (ro)
RU (1) RU2263506C2 (ro)
SK (1) SK286313B6 (ro)
UA (1) UA73972C2 (ro)
WO (1) WO2001062256A1 (ro)
ZA (1) ZA200206042B (ro)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
FR2868314B1 (fr) * 2004-04-05 2008-10-24 Therabel Pharmaceuticals Ltd Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
EP2468269A1 (en) 2010-11-26 2012-06-27 Universitätsklinikum Münster Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation
BE1028879B1 (fr) 2020-12-11 2022-07-12 Europharmaceuticals Comprimé à libération prolongée de la molsidomine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014680A1 (en) * 1990-03-28 1991-10-03 Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt Inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine or salts formed with cyclodextrin derivatives, preparation thereof and pharmaceutical compositions containing the same
EP0624370A1 (de) * 1993-05-11 1994-11-17 Hoechst Aktiengesellschaft Galenische Zubereitungen von Molsidomin
EP0714661A1 (de) * 1994-12-03 1996-06-05 Hoechst Aktiengesellschaft Verfahren zur Herstellung Molsidomin-haltiger Tabletten
MD776C2 (ro) * 1990-03-28 1998-05-31 Therabel Industries S.A. Complecşi de incluziune a 3-morfolino-sidnoniminei sau a sărurilor ei, sau a izomerului ei tautomeric cu ciclordeătrină, sau cu derivaţii ei, procedeu de obţinere a lor, compoziţii farmaceutice care îi conţin, procedeu de obţinere a lor şi de tratarea a stenocardiei, sau a bolii ischemice
MD1419F2 (ro) * 1994-04-26 2000-02-29 Therabel Research Sa Complecsi de incluziune pe baza de SIN-1A si ciclodextrina, compozitii farmaceutice si truse pe baza lor, procedeu de preparare a complecsilor de incluziune si metoda de tratament

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3522191A1 (de) * 1985-06-21 1987-01-15 Cassella Ag Photostabilisierung von sydnoniminen
CN1006522B (zh) * 1986-04-30 1990-01-24 田道制药有限公司 缓放性制剂的制备方法
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
EP0707465A4 (en) * 1993-07-08 1997-04-16 Cygnus Therapeutic Systems MONOLITHIC MATRIX TRANSDERMAL DELIVERY SYSTEM
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
JPH09114680A (ja) * 1995-10-19 1997-05-02 Fuji Xerox Co Ltd シーケンス制御装置
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
AU9496798A (en) * 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014680A1 (en) * 1990-03-28 1991-10-03 Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt Inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine or salts formed with cyclodextrin derivatives, preparation thereof and pharmaceutical compositions containing the same
MD679G2 (ro) * 1990-03-28 1997-11-30 Chinoin Gyogyszer -Es Vegyeszeti Termekek Gyara Rt. Complecşi de incluziune a N-etoxicarbonil-3-morfolino-sidnoniminei sau sărurile lui cu ciclodextrinăsau cu derivaţii ei, prepararea acestora şi compoziţii farmaceutice care le conţin, procedeu de obţinere a lor şi procedeu de tratare
MD776C2 (ro) * 1990-03-28 1998-05-31 Therabel Industries S.A. Complecşi de incluziune a 3-morfolino-sidnoniminei sau a sărurilor ei, sau a izomerului ei tautomeric cu ciclordeătrină, sau cu derivaţii ei, procedeu de obţinere a lor, compoziţii farmaceutice care îi conţin, procedeu de obţinere a lor şi de tratarea a stenocardiei, sau a bolii ischemice
EP0624370A1 (de) * 1993-05-11 1994-11-17 Hoechst Aktiengesellschaft Galenische Zubereitungen von Molsidomin
MD1419F2 (ro) * 1994-04-26 2000-02-29 Therabel Research Sa Complecsi de incluziune pe baza de SIN-1A si ciclodextrina, compozitii farmaceutice si truse pe baza lor, procedeu de preparare a complecsilor de incluziune si metoda de tratament
EP0714661A1 (de) * 1994-12-03 1996-06-05 Hoechst Aktiengesellschaft Verfahren zur Herstellung Molsidomin-haltiger Tabletten

Also Published As

Publication number Publication date
HUP0300607A2 (hu) 2003-08-28
PL201631B1 (pl) 2009-04-30
CZ301993B6 (cs) 2010-09-01
MD3119B2 (ro) 2006-08-31
ATE296632T1 (de) 2005-06-15
BG66111B1 (bg) 2011-05-31
DZ3273A1 (fr) 2001-08-30
DE60111196D1 (de) 2005-07-07
FR2805462A1 (fr) 2001-08-31
HUP0300607A3 (en) 2006-02-28
JP2003523981A (ja) 2003-08-12
BR0108041A (pt) 2002-10-29
EP1265614A1 (fr) 2002-12-18
AU2001240653B9 (en) 2005-10-27
BG107027A (bg) 2003-04-30
CA2400886A1 (fr) 2001-08-30
WO2001062256A1 (fr) 2001-08-30
DE60111196T2 (de) 2006-05-11
AU4065301A (en) 2001-09-03
FR2805462B1 (fr) 2003-08-15
HRP20020692A2 (en) 2004-02-29
RU2002121503A (ru) 2004-03-20
PL357550A1 (en) 2004-07-26
EP1265614B1 (fr) 2005-06-01
BR0108041B1 (pt) 2013-06-18
BE1013487A3 (fr) 2002-02-05
ES2241803T3 (es) 2005-11-01
AU2001240653B2 (en) 2005-05-26
NZ520691A (en) 2004-07-30
HK1050138B (zh) 2005-07-29
EE200200472A (et) 2003-12-15
US7767227B2 (en) 2010-08-03
IL151205A0 (en) 2003-04-10
MD20020212A (ro) 2002-12-31
UA73972C2 (en) 2005-10-17
OA12183A (fr) 2006-05-09
US20030045522A1 (en) 2003-03-06
HU229799B1 (en) 2014-07-28
KR100814191B1 (ko) 2008-03-17
NO329495B1 (no) 2010-11-01
EE05098B1 (et) 2008-12-15
NO20024043D0 (no) 2002-08-23
IS6504A (is) 2002-08-14
YU62202A (sh) 2006-01-16
RS50291B (sr) 2009-09-08
MXPA02008262A (es) 2004-04-05
SK12202002A3 (sk) 2002-12-03
JP4945043B2 (ja) 2012-06-06
BRPI0108041B8 (pt) 2021-05-25
IL151205A (en) 2011-01-31
CN1419451A (zh) 2003-05-21
HRP20020692B1 (en) 2011-10-31
KR20020081323A (ko) 2002-10-26
HK1050138A1 (en) 2003-06-13
IS2446B (is) 2008-11-15
CA2400886C (fr) 2011-04-19
MA25576A1 (fr) 2002-10-01
RU2263506C2 (ru) 2005-11-10
CN100396284C (zh) 2008-06-25
NO20024043L (no) 2002-08-23
SK286313B6 (en) 2008-07-07
PT1265614E (pt) 2005-10-31
ZA200206042B (en) 2003-07-29

Similar Documents

Publication Publication Date Title
US5672356A (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
PE20030399A1 (es) Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa
EE200100505A (et) Modifitseeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis, hüdrofiilnekontrollitud vabanemisega preparaat, selle valmistamismeetod ja kasutamine ning ravimvorm
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
NO20024733D0 (no) Hydrofile molekyl¶rdisperse lösninger av karvedilol
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
ES2610469T3 (es) Nuevas formulaciones farmacéuticas útiles en el tratamiento del insomnio
EP1885333A1 (en) Pharmaceutical formulation of apomorphine for buccal administration
IE20001017A1 (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
KR900004326A (ko) 디히드로에르고톡신 및 그의 산 부가염의 분산성 정제
MD3119C2 (ro) Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
JP2009507850A5 (ro)
RS20060413A (en) Non-disintegrating oral solid composition of high dose of water soluble drugs
NO20032581L (no) Farmasöytisk formulering av gepiron for oral administrering
RU2006134695A (ru) Пероральная композиция с пролонгированным высвобождением молсидомина для лечения атеросклероза
Christensen et al. Pharmacokinetics and dynamic response of plain and slow release isradipine formulations in moderately hypertensive patients
PE20001336A1 (es) Composicion que contiene un miorelajante y un antiinflamatorio no esteroideo para el tratamiento de afecciones dolorosas asociadas a contracturas o espamos musculares
WO1999048483A8 (en) (-)-phenylpropanolamine as a sympathomimetic drug

Legal Events

Date Code Title Description
FG4A Patent for invention issued